<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35412216</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2193-8253</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurology and therapy</Title>
          <ISOAbbreviation>Neurol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study.</ArticleTitle>
        <Pagination>
          <StartPage>815</StartPage>
          <EndPage>834</EndPage>
          <MedlinePgn>815-834</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40120-022-00345-9</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We investigated the safety and explore potential efficacy of batoclimab administered subcutaneously in Chinese patients with generalized myasthenia gravis (gMG).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, double-blinded, placebo-controlled, parallel phase II study was conducted. First, in the double-blinded treatment period, eligible patients received batoclimab (680 mg), batoclimab (340 mg), or placebo on days 1, 8, 15, 22, 29, and 36. In the open-label treatment period, patients received batoclimab (340 mg) on days 50, 64, and 78. In the follow-up period, patients were examined on days 92, 106, and 120. The primary endpoint was Myasthenia Gravis Activities of Daily Living (MG-ADL) score change on day 43 from baseline.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 30 eligible patients were enrolled, with 11, 10, and 9 patients in the batoclimab 680 mg, batoclimab 340 mg, and placebo groups, respectively. MG-ADL score changes from baseline to day 43 were -2.2 ± 0.9, -4.7 ± 0.6, and -4.4 ± 1.0 in the placebo, batoclimab 340 mg, and 680 mg groups, respectively. Similar changes were observed in Quantitative Myasthenia Gravis, Myasthenia Gravis Composite, and 15-item Myasthenia Gravis Quality of Life scores in the placebo, batoclimab 340 mg, and 680 mg groups, respectively. The proportion of patients with clinically significant improvement on day 43 was higher in the batoclimab groups. On day 120, all four scales in the placebo group had more significant improvement compared with the batoclimab groups, with total serum IgG levels reaching a plateau. No death or treatment-emergent adverse events (TEAEs) led to study discontinuation.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Batoclimab is effective and safe in Chinese patients with gMG.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This study was registered at ClinicalTrials.gov (NCT04346888) on 15 April 2020, with the first patient enrolled on 23 July 2020.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yan</LastName>
            <ForeName>Chong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Huashan Rare Disease Center, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Center for Neurological Disorders, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Duan</LastName>
            <ForeName>Rui-Sheng</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yang</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hai-Feng</ForeName>
            <Initials>HF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Zhangyu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beijing Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Hongyu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiao-Li</ForeName>
            <Initials>XL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Lidong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jialin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beijing Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Harbour BioMed, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Harbour BioMed, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiaoxiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Harbour BioMed, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Chongbo</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-9481-1418</Identifier>
            <AffiliationInfo>
              <Affiliation>Huashan Rare Disease Center, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China. zhao_chongbo@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Center for Neurological Disorders, Shanghai, China. zhao_chongbo@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04346888</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Ther</MedlineTA>
        <NlmUniqueID>101637818</NlmUniqueID>
        <ISSNLinking>2193-6536</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Batoclimab</Keyword>
        <Keyword MajorTopicYN="N">Efficacy</Keyword>
        <Keyword MajorTopicYN="N">Generalized myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Neonatal Fc receptor</Keyword>
        <Keyword MajorTopicYN="N">Safety</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>12</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35412216</ArticleId>
        <ArticleId IdType="pmc">PMC9095773</ArticleId>
        <ArticleId IdType="doi">10.1007/s40120-022-00345-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s40120-022-00345-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;2021:10.</Citation>
        </Reference>
        <Reference>
          <Citation>Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981. doi: 10.3389/fneur.2020.596981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.596981</ArticleId>
            <ArticleId IdType="pmc">PMC7734299</ArticleId>
            <ArticleId IdType="pubmed">33329350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Tian DC, Zhang C, et al.  Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063. doi: 10.1016/j.lanwpc.2020.100063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lanwpc.2020.100063</ArticleId>
            <ArticleId IdType="pmc">PMC8315547</ArticleId>
            <ArticleId IdType="pubmed">34327399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30. doi: 10.1038/s41572-019-0079-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-019-0079-y</ArticleId>
            <ArticleId IdType="pubmed">31048702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuercher AW, Spirig R, Baz Morelli A, Rowe T, Kasermann F. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18:102366. doi: 10.1016/j.autrev.2019.102366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2019.102366</ArticleId>
            <ArticleId IdType="pubmed">31404703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20:102712. doi: 10.1016/j.autrev.2020.102712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2020.102712</ArticleId>
            <ArticleId IdType="pubmed">33197578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard JF, Jr, Bril V, Burns TM, et al.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92:e2661–e2673. doi: 10.1212/WNL.0000000000007600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000007600</ArticleId>
            <ArticleId IdType="pmc">PMC6556100</ArticleId>
            <ArticleId IdType="pubmed">31118245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard JF, Jr, Bril V, Vu T, et al.  Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526–536. doi: 10.1016/S1474-4422(21)00159-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(21)00159-9</ArticleId>
            <ArticleId IdType="pubmed">34146511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bril V, Benatar M, Andersen H, et al.  Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96:e853–e865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8105899</ArticleId>
            <ArticleId IdType="pubmed">33219142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap DYH, Hai J, Lee PCH, et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci. 2021;20:21.</Citation>
        </Reference>
        <Reference>
          <Citation>Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52:1487–1489. doi: 10.1212/WNL.52.7.1487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.52.7.1487</ArticleId>
            <ArticleId IdType="pubmed">10227640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–772. doi: 10.1111/j.1749-6632.1998.tb11015.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1998.tb11015.x</ArticleId>
            <ArticleId IdType="pubmed">9668327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns TM, Conaway M, Sanders DB, Composite MG, Group M-QS. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74:1434–1440. doi: 10.1212/WNL.0b013e3181dc1b1e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181dc1b1e</ArticleId>
            <ArticleId IdType="pmc">PMC3462556</ArticleId>
            <ArticleId IdType="pubmed">20439845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns TM, Sadjadi R, Utsugisawa K, et al.  International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54:1015–1022. doi: 10.1002/mus.25198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25198</ArticleId>
            <ArticleId IdType="pubmed">27220659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF, Group RS. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020;267:1991–2001. doi: 10.1007/s00415-020-09770-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09770-y</ArticleId>
            <ArticleId IdType="pmc">PMC7320935</ArticleId>
            <ArticleId IdType="pubmed">32189108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peter HH, Ochs HD, Cunningham-Rundles C, et al.  Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146:479–491e475. doi: 10.1016/j.jaci.2020.07.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2020.07.016</ArticleId>
            <ArticleId IdType="pmc">PMC7471860</ArticleId>
            <ArticleId IdType="pubmed">32896308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling LE, Hillson JL, Tiessen RG, et al.  M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther. 2019;105:1031–1039. doi: 10.1002/cpt.1276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpt.1276</ArticleId>
            <ArticleId IdType="pmc">PMC6587432</ArticleId>
            <ArticleId IdType="pubmed">30402880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blumberg LJ, Humphries JE, Jones SD, et al.  Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019;5:eaax9586. doi: 10.1126/sciadv.aax9586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aax9586</ArticleId>
            <ArticleId IdType="pmc">PMC6920022</ArticleId>
            <ArticleId IdType="pubmed">31897428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Incorporation MP. Vivacity-MG phase 2 interim analysis topline results. In: Incorporation MP (ed) Investor and analyst conference call. Online: Momenta Pharmaceuticals Incorporation, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol. 2014;5:682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4306297</ArticleId>
            <ArticleId IdType="pubmed">25674083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Md AH, Deb KP, Hossain MA, Mannan KA, Mostafa G, Hossain MM. Correlation between serum cholesterol and serum albumin level in childhood nephrotic syndrome. Urol Nephrol Open Access J. 2016;3:00086.</Citation>
        </Reference>
        <Reference>
          <Citation>Urquhart L. Cholesterol fears rock Immunovant. Evaluate Vantage, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Kiessling P, Lledo-Garcia R, Watanabe S, et al.  The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9:25. doi: 10.1126/scitranslmed.aan1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aan1208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guptill JT, Juel VC, Massey JM, et al.  Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49:472–479. doi: 10.1080/08916934.2016.1214823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08916934.2016.1214823</ArticleId>
            <ArticleId IdType="pmc">PMC5440840</ArticleId>
            <ArticleId IdType="pubmed">27684107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohkubo A, Okado T, Sakurasawa T, et al.  Removal characteristics of immunoadsorption with the tryptophan-immobilized column using conventional and selective plasma separators in the treatment of myasthenia gravis. Ther Apher Dial. 2019;23:271–278. doi: 10.1111/1744-9987.12820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1744-9987.12820</ArticleId>
            <ArticleId IdType="pubmed">31025833</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
